Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma

September 30th 2024

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma

September 30th 2024

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Anito-Cel Yields 100% Response Rate in R/R Myeloma

September 30th 2024

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Durcabtagene Autoleucel Yields High Response Rates in R/R Myeloma

September 30th 2024

Durcabtagene autoleucel generated responses with a tolerable safety profile in relapsed/refractory multiple myeloma.

Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma

September 27th 2024

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT

September 27th 2024

Daratumumab/lenalidomide maintenance increased MRD-negative conversion rates vs lenalidomide alone in newly diagnosed multiple myeloma after transplant.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

September 27th 2024

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

September 27th 2024

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

September 27th 2024

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Daratumumab Regimen Yields Durable MRD-Negativity in Newly Diagnosed Multiple Myeloma

September 26th 2024

Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

September 26th 2024

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment

September 25th 2024

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma

September 24th 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

FDA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

September 20th 2024

The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.

Subcutaneous Daratumumab Quadruplet Approaches EU Approval for Newly Diagnosed Myeloma

September 20th 2024

The EMA's CHMP has recommended the approval of subcutaneous daratumumab plus VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

September 18th 2024

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

September 18th 2024

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan

September 18th 2024

Japan’s Ministry of Health, Labour, and Welfare has accepted the NDA for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma.

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

September 17th 2024

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma

September 17th 2024

China’s NMPA granted breakthrough therapy designation to belantamab mafodotin plus bortezomib and dexamethasone in relapsed/refractory myeloma.